ArticleCell2018
Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 152 citations in OpenAlex.
- Autophagy modulation in cancer.Nature reviews. Drug discovery · 2026Review
- Mitophagy interacts with mitochondrial dynamics and biogenesis, acting as a double-edged sword in digestive cancer.iScience · 2026Review
- Prognostic and immunological implications of a mitophagy-associated gene signature in bladder cancer.Translational andrology and urology · 2026Article
- Regulated cell death programs shaping cancer therapy.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Mitophagy-driven multidimensional regulation of tumor immune evasion and context-dependent therapeutic strategies.Journal of translational medicine · 2026Review
- A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors.Frontiers in immunology · 2026Review
- PINK1 dysfunction in hepatocellular carcinoma fosters immune evasion and disease progression by promoting neutrophil infiltration.Journal for immunotherapy of cancer · 2025Article
- SYK regulates Schwann cell metabolic reprogramming to promote axonal regeneration in immune-mediated neuropathy.Journal of neuroinflammation · 2025Article
- The immune microenvironment of colorectal cancer.Nature reviews. Cancer · 2025Review
- Parkin modulates the hepatocellular carcinoma microenvironment by regulating PD-1/PD-L1 signalling.Journal of advanced research · 2025Article
- Self-Powered α Radionuclide Nanomedicine: Mitochondria-Targeted Multimodal Energy Recycling for Amplified Radioimmunotherapy.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Dual-key cooperatively activated DNA regulator for controlling mitochondria-lysosome interactions.Nature communications · 2025Article
- Identification and characterization of mitochondrial autophagy-related genes in osteosarcoma and predicting clinical prognosis.Scientific reports · 2025Article
- The role of mitochondrial biogenesis, mitochondrial dynamics and mitophagy in gastrointestinal tumors.Cancer cell international · 2025Review
- Transcriptomic profiles of single-cell autophagy-related genes (ATGs) in lung diseases.Cell biology and toxicology · 2025Article
- mtSTAT3 suppresses rheumatoid arthritis by regulating Th17 and synovial fibroblast inflammatory cell death with IL-17-mediated autophagy dysfunction.Experimental & molecular medicine · 2025Article
- Gut microbiota interplay with autophagy-EMT dynamics in colorectal cancer.Frontiers in cell and developmental biology · 2025Review
- Elucidation of the mechanism Underlying the promotion of ferroptosis and enhanced antitumor immunity by citrus polymethoxyflavones in CRC cells.Frontiers in pharmacology · 2025Article
- Mechanisms and cross-talk of regulated cell death and their epigenetic modifications in tumor progression.Molecular cancer · 2024Review
- Autophagy and its role in gastrointestinal diseases.World journal of gastroenterology · 2024Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
28 authors at 15 institutions in 4 countries.
Paul K ZieglerInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt am, Germany; Institute of Pathology, Frankfurt University Hospital, 60590 Frankfurt, Germany.
Julia BollrathInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt am, Germany.
Charles K PallangyoInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt am, Germany.
Takaji MatsutaniR&D Department, Repertoire Genesis Incorporation, Ibaraki, Osaka 567-0085, Japan.
Özge CanliInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt am, Germany.
Tiago De OliveiraInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt am, Germany.
Michaela A DiamantiInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt am, Germany.
Nina MüllerInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt am, Germany.
Jaba GamrekelashviliDepartment of Nephrology, Medical School Hannover, 30625 Hannover, Germany.
Tracy PutoczkiWalter and Eliza Hall Institute of Medical Research, Melbourne VIC, Australia.
David HorstInstitute of Pathology, Charité- Universitätsmedizin Berlin, 10117 Berlin, Germany.
Arun K MankanInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt am, Germany.
Meryem G ÖnerInstitute of Pathology, Ludwig-Maximilians-University, 80337 Munich, Germany.
Susanna MüllerInstitute of Pathology, Ludwig-Maximilians-University, 80337 Munich, Germany.
Josef Müller-HöckerInstitute of Pathology, Ludwig-Maximilians-University, 80337 Munich, Germany.
Thomas KirchnerInstitute of Pathology, Ludwig-Maximilians-University, 80337 Munich, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Julia Slotta-HuspeninaInstitute of Pathology of the Technical University Munich, 81675 Munich, Germany.
M Mark TaketoDivision of Experimental Therapeutics, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Thomas ReinheckelGerman Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Institute of Molecular Medicine and Cell Research, Faculty of Medicine, Albert-Ludwigs-University Freiburg, 79104 Freiburg, Germany.
Stefan DröseDepartment of Anesthesiology, Frankfurt University Hospital, 60590 Frankfurt am, Germany.
Andrew C LarnerDepartment of Biochemistry and Molecular Biology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Winfried S WelsInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt am, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Matthias ErnstOlivia Newton-John Cancer Research Institute, La Trobe University School of Cancer Medicine, Heidelberg VIC 3084, Australia.
Tim F GretenNational Institutes of Health, National Cancer Institute, Medical Oncology Branch, Bethesda, MD 20892, USA.
Melek C ArkanInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt am, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Institute of Biochemistry II, Goethe University School of Medicine, 60590 Frankfurt am, Germany.
Thomas KornDepartment of Neurology, Klinikum rechts der Isar, Technical University Munich, 81675 Munich, Germany.
Dagmar WirthModel Systems for Infection and Immunity, Helmholtz Centre for Infection Research, Inhoffenstr. 7, 38124 Braunschweig, Germany; Experimental Hematology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Florian R GretenInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt am, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. Electronic address: greten@gsh.uni-frankfurt.de.
Georg Speyer Haus · DEHeidelberg University · DELudwig-Maximilians-Universität München · DEUniversity Hospital Frankfurt · DECharité - Universitätsmedizin Berlin · DEGerman Cancer Research Center · DEHelmholtz Centre for Infection Research · DEKlinikum rechts der Isar · DEKyoto University · JPMedizinische Hochschule Hannover · DENational Institutes of Health · USOlivia Newton-John Cancer Wellness & Research Centre · AUTechnical University of Munich · DEVirginia Commonwealth University · USWalter and Eliza Hall Institute of Medical Research · AU
Funding
Clinical protocols for the treatment of GI cancerZIABC011343 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GRETEN, TIM · 2010 to 2025
$4.8MImmune suppressor mechanisms in patients with GI cancerZIABC011344 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GRETEN, TIM · 2010 to 2025
$2.2MIntramural NIH HHS Z99 CA999999
Abstract
In colorectal cancer patients, a high density of cytotoxic CD8
Indexed as
Adaptive ImmunityMitophagyAnimalsAzoxymethaneCD8-Positive T-LymphocytesCell Membrane PermeabilityColorectal NeoplasmsCytokinesDendritic CellsFemaleFerrous CompoundsHumansInterferon-gammaIntestinal MucosaLysosomesMaleAzoxymethaneCytokinesFerrous CompoundsInterferon-gammaStat3 protein, mouseSTAT3 Transcription Factoradaptive immunityantigen processingcolon cancercross dressingintestinal epithelial cellslysosomal membrane permeabilizationmitophagyStat3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.